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Abstract In recent years, multiple criteria decision anal-
ysis (MCDA) has emerged as a likely alternative to address
shortcomings in health technology assessment (HTA) by
offering a more holistic perspective to value assessment and
acting as an alternative priority setting tool. In this paper,
we argue that MCDA needs to subscribe to robust
methodological processes related to the selection of objec-
tives, criteria and attributes in order to be meaningful in the
context of healthcare decision making and fulfil its role in
value-based assessment (VBA). We propose a method-
ological process, based on multi-attribute value theory
(MAVT) methods comprising five distinct phases, outline
the stages involved in each phase and discuss their rele-
vance in the HTA process. Importantly, criteria and attri-
butes need to satisfy a set of desired properties, otherwise
the outcome of the analysis can produce spurious results and
misleading recommendations. Assuming the methodologi-
cal process we propose is adhered to, the application of
MCDA presents three very distinct advantages to decision
makers in the context of HTA and VBA: first, it acts as an
instrument for eliciting preferences on the performance of
alternative options across a wider set of explicit criteria,
leading to a more complete assessment of value; second, it
allows the elicitation of preferences across the criteria
themselves to reflect differences in their relative impor-
tance; and, third, the entire process of preference elicitation
can be informed by direct stakeholder engagement, and can
therefore reflect their own preferences. All features are fully
transparent and facilitate decision making.
Key Points for Decision Makers
Multiple criteria decision analysis (MCDA) has
emerged as a likely alternative approach to economic
evaluation in the context of health technology
assessment (HTA). However, there is no sufficient
methodological guidance on how to design, conduct
and implement MCDA as part of HTA, including
how to select criteria appropriately.
An MCDA-based methodological framework in the
context of HTA could be divided into the phases of
problem structuring, model building, model
assessment, model appraisal, and action plans. For
the analysis to be robust and for decision
recommendations to be ultimately meaningful,
criteria and attributes should adhere to a number of
properties.
The resulting MCDA index score could act as a more
encompassing measure of value given that multiple
benefit dimensions are incorporated. Consideration
of purchasing costs could be used to derive the
different options’ incremental cost value ratio
(ICVR) and contribute to priority setting and
resource allocation.
1 Introduction
The use of economic evaluation methods, particularly cost-
effectiveness analysis (CEA) and cost-utility analysis
(CUA), to assess the incremental benefit of new medical
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technologies in relation to best alternative care has
increased considerably over the past 2 decades. In this
context, the use of the quality-adjusted life-year (QALY)
has been established as the preferred measure of health
gain across many settings [1–4]. This is despite its frequent
dependence on restrictive assumptions [5], the non-align-
ment of public versus patients’ decision utilities, which
would differ from their respective experienced utilities1
[6], and the reliance on generic tools, such as the EQ-5D,
that may not reflect patient experience adequately [7–9].
At the same time, there is increased recognition that
economic evaluation has limitations because it does not
capture a number of important dimensions of value, and is
therefore lacking in comprehensiveness. In partial recog-
nition of that, economic evaluation has recently evolved
into a deliberative process across different settings,
whereby independent decision-making committees often
allow for other dimensions of value to be considered, at
least implicitly.
Additionally, there is increasing evidence that decision
makers are reluctant to make coverage recommendations
on economic evaluation alone [10] and, consequently,
‘value’ based on economic evaluation results could be
informed by additional dimensions of benefit. Recently,
decision makers in England and Wales considered addi-
tional parameters of benefit on an ad hoc basis [11],
highlighting the need to seek a broader and more trans-
parent assessment methodology [12, 13], in the context of
value-based pricing [14–17].
Even under such enhanced settings, the decision-making
framework often lacks transparency, not least because
different stakeholders attach different value judgements to
the criteria considered. Consequently, value assessment is
not simply a question of what additional benefits to con-
sider and possibly include in the decision-making process,
but, importantly, involves how to arrive at a clear process
that elicits and accounts for the preferences of different
stakeholders in a transparent way. The ongoing debate in
the UK on value-based pricing is a testament to these issues
[18].
Overall, the lack of comprehensiveness, the emerging ad
hoc and non-systematic use of additional dimensions of
value and the lack of transparency in making value
judgements often lead to inconsistencies in the appraisal
process. The consequence is ‘unexplained’ decision
heterogeneity, with important implications for fairness,
equity and resource allocation.
The development of alternative methodological
approaches for value assessment of medical technologies
that would overcome the above limitations could contribute
to a more complete framework of value assessment and, in
turn, lead to more efficient resource allocation.
In recent years, multiple criteria decision analysis
(MCDA) has emerged as a likely alternative to address the
current shortcomings of Health Technology Assessment
(HTA) based on economic evaluation [19–24]. One of the
conclusions of a recent review of MCDA approaches
adopted in healthcare was that decision makers display a
positive attitude towards its potential to improve decision
making [25]. Conceptually, there are three main reasons
why MCDA could provide a useful alternative to economic
evaluation-based HTA processes. The first relates to the
inclusion of a comprehensive list of value dimensions in an
explicit manner, beyond what economic evaluation meth-
ods currently capture. This enables value assessment to be
conducted in an encompassing manner and, in principle,
addresses a key limitation of economic evaluation. The
second relates to the assignment of quantitative weights
across the different evaluation criteria. In doing so, the
relative importance of various value dimensions is explic-
itly incorporated, improving the transparency of the pref-
erence-elicitation process. The third is stakeholder
participation and the possibility to include all relevant
stakeholders in the value-assessment process. This is both
insightful—enabling stakeholder views to be heard in a
dynamic environment, where all inputs are considered prior
to making decisions about coverage—and politically cor-
rect, increasing the legitimacy of decision processes, as all
stakeholder views are accounted for in an open and trans-
parent way.
Despite the above, the methodological details of MCDA
implementation in the context of healthcare decision
making have not been sufficiently discussed, and there is
no adequate guidance on how MCDA should be conducted
in HTA, particularly in relation to which criteria to incor-
porate and how.
In this paper, we outline a methodological process for
the development of a robust MCDA framework and debate
its implementation in the context of HTA. In doing so, we
provide a broad classification of MCDA methods while
also accounting for and building on the classifications
proposed in the literature [26–32]. We then focus on value-
based methods, specifically MAVT methods, and argue in
favour of using these because of their comprehensive nat-
ure. Further, we argue that several key principles need to be
fulfilled in order for any MCDA framework to be
methodologically sound and for the results produced to be
robust and policy relevant. These principles apply to the
MCDA main phases and stages as well as to the properties
that the selected criteria and attributes need to satisfy,
while establishing their relevance in the context of HTA
and value-based assessment (VBA). We discuss these
1 ‘‘Decision utility’’ refers to the preference or desire for an outcome
that has not occurred in contrast to ‘‘experienced utility’’ which refers
to the actual hedonic experience of an outcome [6].
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principles and their implications in the context of HTA by
drawing on concrete examples. Finally, we discuss a
number of practical issues relating to the use of MCDA in
HTA and provide a link to policy making.
2 A Methodological Framework Applying MCDA
Principles in HTA and Value Assessment
of Medical Technologies
2.1 MCDA in the Context of Multi-Attribute Value
Theory
MCDA is both an approach and a group of techniques
aiming to aid decision making by laying out the problem,
objectives and available options in a clear and transparent
way. Different MCDA methods exist, with variable degrees
of complexity making use of different analytic models.
These methods can be broadly categorised by ‘school of
thought’, notably (1) value-measurement methods, includ-
ing (multi-attribute) value theory and utility theory meth-
ods, (2) ‘satisficing’ and aspiration level methods, (3)
outranking methods, and (4) fuzzy and rough sets methods
[26–29]. However, no universal categorisation of MCDA
methods exists, and others have proposed groupings that
differ from the above [30–32]. Each MCDA method has its
own advantages and disadvantages. The choice of method
is informed by the type of problem to be addressed, the
type of judgements required, the set of axioms employed to
support decision making, and the kind of responses needed.
Some methods address choice problems, while others
address ranking problems or classification and sorting
problems.
The methodological process we are proposing in this
paper for the context of HTA pertains to the category of
value-measurement methods. This is predominantly
because of the multiple problems that can be addressed, the
simplicity of the judgements required and the relatively
limited restrictions imposed by the axioms employed. The
value-measurement methods category is widely used in
healthcare because of these features. Nevertheless, some
aspects (e.g. the MCDA phases and the criteria properties)
are applicable across different MCDA methods beyond the
value-measurement methods category.
Value-measurement methods usually aim to address
ranking or choice problems, ordering a set of alternative
options with respect to their performance on a number of
objectives or criteria, through the production of overall
numerical value scores. A value (or real number) V is
associated with the performance of an alternative a, in
order to produce an ordering of preferences for all alter-
natives being considered, while being consistent with the
assumptions of complete and transitive preferences. These
methods include linear additive methods, multi-attribute
value theory (MAVT) methods for deterministic conse-
quences, and multi-attribute utility theory (MAUT)
methods.
We argue in favour of MAVT methods because of their
comprehensiveness and methodological robustness [27], as
well as their ability to reduce ambiguity and motivational
biases. The MAVT methods framework adheres to a
number of phases and stages and includes (1) the definition
of objectives, (2) the selection of criteria, (3) the scoring of
options, and (4) the assignment of weights to the selected
criteria.
The choice of technique that will inform parts of the
process, including scoring, weighing and aggregation, is
an important decision. Under MAVT methods, partial
value functions for individual criteria are constructed in
the first instance and are subsequently aggregated.
Essentially, value functions reflect decision makers’
preferences for different levels of performance on the
attribute scale (Fig. 1). Importantly, the assumptions
required for the formation of the partial value functions
are interlinked with the aggregation type of technique
used. In the sections that follow, we present and discuss
these fundamental principles in the context of healthcare
decision making and use examples to illustrate their
application and interpretation.
2.2 MCDA Phases Under MAVT Methods
While the general features of MCDA phases have already
been discussed elsewhere [26], the MCDA process could
be divided into five distinct phases in the context of HTA;
these would be (1) problem structuring, (2) model building,
(3) model assessment, (4) model appraisal, and (5) devel-
opment of action plans (Fig. 2).
Problem structuring involves an understanding of the
problem to be addressed. This includes key concerns,
envisaged goals, relevant stakeholders that may participate
in or contribute to decisions, and identification of uncer-
tainties in terms of a new technology’s clinical evidence
and its quality.
The phases of model building, model assessment and
model appraisal involve the construction of decision
makers’ value judgements within and across the criteria of
interest, while being consistent with a set of assumptions,
aiming to help decision makers elicit and order their
preferences across the alternative options assessed. For
example, if overall survival (OS) is a criterion, then the
respective value associated with a range of plausible
incremental OS gains (e.g. 3, 6, 9, or more months) is of
interest to know and so is the intensity with which stake-
holders would prefer certain attribute levels within the
same criterion (e.g. an increase in OS from 3 to 6 months
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could be of greater value to some stakeholders than an
increase in OS from 6 to 9 months) (Fig. 1).
Finally, given that the outcome of the analysis needs to
inform decision making, action plans need to be shaped
involving a clear pathway for result implementation. In the
case of HTA, this could involve prioritising resource
allocation as part of coverage decisions that take place
following the evaluation of new medical technologies.
Although these five phases are presented as part of a
linear process, in reality they could be part of an iterative
Fig. 1 Value function for
scoring the performance of
alternative options
Fig. 2 Multiple criteria decision analysis (MCDA) methodological process in the context of health technology assessment
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process, moving from a later step back to a previous step
before advancing. For example, as part of the model
assessment phase, it could become evident that some of the
criteria do not possess all the required properties (see Sect.
3), in which case the model should be adapted accordingly
as part of the model-building phase.
2.3 MCDA Stages under MAVT Methods
2.3.1 Problem Structuring
Each MCDA phase comprises a number of stages (Fig. 2).
Initially, as part of the problem-structuring phase, the
decision context needs to be established where the problem
under investigation and the aims of the analysis are clearly
outlined and defined, and relevant decision makers and
other key stakeholders are identified. For example, in the
context of VBA of a new technology, the decision problem
may be to assess the new technology’s costs and benefits
from a broader societal perspective relative to other ther-
apeutic alternatives to identify the most valuable treatment
for a health system. The decision makers in this context
would be payers or insurers (including commissioners of
care), whereas healthcare professionals, patients and their
carers, technology suppliers and methodology experts,
including decision-analysis experts conducting and co-or-
dinating the MCDA process, would be the relevant stake-
holders. The process of identifying the appropriate decision
makers and stakeholders would be specific to the country
or setting. This particular phase could be conducted by
researchers or, alternatively, an HTA agency in settings
where such an agency exists.
2.3.2 Model Building
Subsequently, as part of the model-building phase, objec-
tives need to be established and/or relevant criteria iden-
tified to reflect decision makers’ goals and areas of
concern. Additionally, attributes need to be selected to
operationalise these criteria and enable their assessment.
This involves a deliberative process in order to obtain a
good understanding of the decision problem and what
decision makers want to achieve (objectives), through
which the values of concern (criteria) will eventually
emerge. The assessment takes place based on the selected
criteria and attributes. For example, when evaluating a new
medical technology relative to an older one, criteria from a
number of domains could be selected, such as therapeutic
benefit, safety profile, burden of illness, innovation level
and socioeconomic impact [22, 33]. In principle, these
criteria domains would emerge from decision makers’
values of concern; in practice, they could be identified from
the literature in combination with semi-structured
interviews with decision makers. Uncertainty of evidence,
mainly relating to relevance, validity and the overall
quality of the available evidence, is another crucial
parameter that should be considered. This phase could be
carried out by MCDA researchers in collaboration with the
decision makers and possibly stakeholders whose value
concerns should be considered.
As part of the model-building phase, the alternative
options need to be selected, and evidence on their perfor-
mance across criteria/attributes needs to be identified. For
example, the alternatives for the treatment of a particular
disease must be identified, and data on observed alterna-
tives or expected performance across criteria must be col-
lected either through secondary research (e.g. from
published randomized controlled trial results) or through
primary research if data are not available from secondary
sources (e.g. clinical or patient opinion). Following the
completion of this stage, attribute ranges will be formed
based on observed or expected performance of different
treatment options that shall inform the next stages of the
process. Depending on the technique used, plausible attri-
bute ranges can be set by taking into account any pre-
existing preferences of decision makers in relation to
maximum and minimum allowable performance levels on
the different criteria. For example, the OS gains of three
different treatments could range from 2 to 12 months, and
therefore the respective attribute range should be broad
enough to include all these gains (i.e. at least from 2 to 12
months). It could also be the case that the decision maker is
not willing to consider any treatments offering incremental
OS gains of less than 3 months; in this case, the attribute
range could be rescaled and adapted to decision makers’
revealed preferences (i.e. to range from a minimum of 3
months upwards), with the treatment option offering 2
months of OS excluded from the analysis.
2.3.3 Model Assessment
In the context of the model-assessment phase, the perfor-
mance of options against the identified criteria must be
assessed (i.e. scoring, which would deliver intra-criteria
information), and criteria must be weighed according to
their relative importance (i.e. weighing, which would
deliver inter-criteria information), revealing preferences for
different levels of performance within criteria and across
different criteria, respectively. In the case of the OS
example, a numerical value score would be assigned to the
options being evaluated with regards to their performance
on OS gains. As part of MAVT methods, the construction
of value functions can take place through different tech-
niques (direct rating, indirect, bisection techniques). All
require the definition of attribute levels that will form the
minimum and maximum points of the value scale.
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Although the two limits of the attribute range are usually
assigned a value of 0 and 100, reflecting the minimum and
maximum points of the value scale, respectively, other
reference points can also be used. Using the OS example, 3
months could be used as the lower reference level and 12
months as the higher reference level, making up the 0 and
100 points of the value scale, respectively. The attribute
performance of the options can then be assessed through
the use of the value functions that will convert their per-
formance into value scores (Fig. 1). The process of scoring
and weighing completes the construction of value
judgements.
A critical aspect in the entire process is the relative
importance of different criteria to decision makers. For this
reason, relative weights are assigned to the criteria by
directly involving decision makers and stakeholders. For
example, in the case of a new drug–indication pair, the
importance of the therapeutic benefits vis-a`-vis an existing
therapeutic alternative (e.g. OS gain and quality-of-life
improvement) could be found to be twice as important as
its safety impact (e.g. adverse events); therefore, the rela-
tive weight of the therapeutic cluster of criteria would be
twice as high as the product’s safety profile. These weights
should only be viewed as scaling constants or trade-off
factors, with no algebraic meaning, assigned to enable
comparability across criteria to reflect their relative
importance.
Methodologically, and contrary to what has been
argued elsewhere [19, 24], we would argue that it is
important for the criteria weights to be derived ex post
following the selection of the alternative treatments and
therefore the setting of the plausible attribute ranges,
rather than ex ante [34]. Theoretically, this is tantamount
to arguing for MAVT models, where the construction of
value functions precedes the criteria weights, rather than
for direct rating methods, where weights are first attached,
based on an ex ante derivation, and the options are then
scored. Conceptually, our preference for the ex post
derivation of weights is justified by the nature of health
technologies and the conditions they treat: the relative
importance of different criteria and their weights are
context specific and depend on the performance of the
alternative options in a given context. By means of an
example, let us assume that, for two treatments (A and
B), weights need to be established for the same criteria
(OS and hepatotoxicity), measured through ‘number of
months gained’ and ‘incidence of hepatotoxicity’,
respectively. The weight assigned to each criterion is very
likely to be different if treatment A ranges between 1 and
10 months (1,10) for OS and from 10 to 11 % (10, 11 %)
for hepatotoxicity, compared with the alternative treat-
ment B, which ranges from 10 to 11 months (10,11) and
from 1 to 10 % (1,10 %), respectively.
2.3.4 Model Appraisal
As part of the appraisal phase, scores and weights are
combined to create a value index (‘aggregating’). The
details of this step may differ according to the type of
aggregation model used, including additive or multiplica-
tive value models depending on the level of preference
independence present among criteria. Empirical evidence
suggests that errors due to the use of additive value
aggregation models are in real settings very small and
considerably smaller than the errors associated with the
wrong aggregation of partial functions that can possibly
result from the incorrect application of more advanced
models [26].
Overall, the individual criteria scores and their respec-
tive weights are combined to produce weighted scores and
are summed to arrive at an overall value score for each
treatment option. In combination with sensitivity analysis,
results are examined to determine the robustness of the
results obtained. The outcome of this process is a ranking
of all treatment options based on their respective value
scores. Decision makers can use this evidence to make
resource-allocation decisions. Throughout the MCDA
stages, including scoring and weighing, the participating
stakeholders are able to interact to exchange views, reach
consensus or simply provide their individual preferences
[26]. To that end, they can compare their individual views
and preferences, they can aggregate such preferences by
voting to reach consensus, and they can share commonly
defined modelling and judgement elements after joint
discussion.
2.4 MCDA Techniques Using MAVT Methods
Several MCDA techniques are available with regards to
scoring, weighing and aggregating. These techniques
mainly relate to the value judgement and preference-elic-
itation processes, and the choice of technique depends on
the particular type of method adopted [29–32].
As part of MAVT methods, the value functions based on
which options are scored can be constructed using different
options: (1) direct rating techniques, (2) indirect tech-
niques, and (3) indifference or bisection techniques [26,
27]. Direct rating techniques involve decisions around the
form of the value function and whether they increase
monotonically (highest attribute level is the most pre-
ferred), decrease monotonically (lowest attribute level is
the most preferred), or range non-monotonically (an
intermediate attribute level is the most preferred).
Indirect techniques generally assume a monotonic
function and involve a series of questions aiming to
uncover decision makers’ preferences by considering dif-
ferences in the attribute scale and their relation to the value
A. Angelis, P. Kanavos
scale. Indifference techniques explore the magnitude of
increments in the attribute scale that correspond to equal
units in the value (preference) scale. Finally, bisection
techniques explore the estimation of points on the attribute
scale that serve as midpoints on the value (preference)
scale.
We would argue in favour of indirect elicitation tech-
niques because of their comprehensiveness and unbiased
nature. This is mainly because decision-makers’ prefer-
ences are first elicited for the complete attribute range, and
options are then scored indirectly using the attributes’
emerging value functions to convert the performance of the
options into value scores, essentially by not revealing any
information about the identity of the respective options at
any point during the process.
An example of such an indirect technique is MACBETH
(Measuring Attractiveness by a Categorical Based Evalu-
ation Technique), a convenient indirect approach to elicit
value functions by only requiring qualitative judgements
about the difference of value between different pairs of
attribute levels [35]. It uses seven semantic categories to
distinguish between the difference of attractiveness
between different attribute levels, ranging between ‘‘no
attractiveness’’ and ‘‘extreme attractiveness’’. Overall, it
builds a quantitative model of values based on qualitative
(verbal) difference judgements, and by analyzing judg-
mental inconsistencies, it facilitates the move from ordinal
preference modelling to cardinal preference modelling.
Once criteria have been scored and value functions have
been derived, criteria weights can be elicited, usually
through a swing weighting technique. Finally, criteria
scores and weights are combined, usually through an
additive aggregation approach.
3 Model-Building and the Construction of a Value
Tree: Properties to Ensure a Robust MCDA
Model
Model building is one of the most important MCDA pha-
ses. Establishing objectives and defining the actual criteria
and attributes are critical stages in this context because
they form the foundation of MCDA analysis. For the
MCDA analysis to be robust and, ultimately, meaningful,
we outline a number of properties to which criteria and
attributes should adhere.
3.1 Objectives, Criteria and Attributes
in the Context of Model Building
Depending on the decision problem under consideration,
the term ‘objective’ or ‘criterion’ may be preferred over the
other, both representing key factors that form the basis of
the analysis. The main difference between the two is that
‘objectives’ usually reflect a direction of preference,
whereas ‘criteria’ do not. Objectives and criteria may be
further decomposed into sub-objectives and sub-criteria;
structuring all objectives and/or criteria in the form of a
tree offers an organised overview of the values under
consideration. This is known as a value tree. The quanti-
tative or qualitative performance measures associated with
criteria or objectives are known as ‘attributes’. Attributes
operationalize the use of criteria and objectives by mea-
suring the extent to which criteria or objectives are
achieved. For example, in the context of a new cancer
treatment, an objective for decision makers could be to
‘maximise life expectancy’; ‘overall survival’ could act as
a criterion, while ‘median number of months from ran-
domisation to death’ could be the relevant attribute
(Fig. 3).
It is not uncommon for a criterion to require more than a
single attribute to be measured adequately. For example, in
the case of ‘tolerability’ as part of the overall safety profile
for a new product, decision makers could benchmark
against the ‘proportion of patients discontinuing the treat-
ment’ as well as the ‘proportion of patients interrupting
treatment or reducing the dose due to adverse events’.
Other examples of value tree hierarchies—made up of
criteria and attributes—together with their respective data
sources are shown in Fig. 3.
Depending on the type of decision problem, the selec-
tion of objectives, criteria and attributes can either precede
or follow the identification of the alternative options
(Table 1) [26, 36, 37]. In the context of ‘value-focused
thinking’, objectives and criteria are selected prior to
specifying or assessing the alternative options, thus being
part of a top-down approach for structuring a value tree
according to which overall objectives or criteria are
decomposed into sub-objectives or sub-criteria [36].
Alternatively, in accordance with the more traditional ‘al-
ternative focused thinking’, a bottom-up approach can be
implemented whereby objectives and criteria emerge fol-
lowing the comparison of the options, based on distin-
guishable attributes that differentiate them [37].
In the context of HTA, a ‘value alternative hybrid
thinking’ logic that contains elements from both approa-
ches could be adopted. Decision makers could have a
generic set of predetermined objectives and criteria
reflecting their values of concern in a top-down approach.
These could then be adapted for the purposes of the deci-
sion-making problem in a bottom-up approach. Thus, the
general values of concern would be tailor made in a
dynamic manner to better assess the differences of alter-
native treatments being compared. For example, decision
makers’ concerns could normally include the existence of
any contraindications or warnings and precautions
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associated with a drug for the indicated patient population
of interest. However, it is possible for all alternative
treatments assessed for a particular disease to have no
contraindications and to have identical minor warnings and
precautions for use. These criteria could therefore be
excluded from that particular assessment on the basis of
non-fundamental importance.
3.2 Key Criteria Properties
In order for the analysis to provide the highest possible
insight and to enhance its actual value to decision makers,
both criteria and attributes need to adhere to a number of
key properties [36–39]. If they do not, the results obtained
through scoring and weighing could be spurious and,
therefore, meaningless for decision making. First, objec-
tives or criteria need to be essential, in that all necessary
objectives of the decision problem should be considered,
and all the critical values under consideration should be
included through the incorporation of the respective crite-
ria. In the context of a value tree, all therapeutic, safety,
burden of illness, innovation and socioeconomic criteria
should be included in the model. Second, criteria need to be
understandable, so that all participants in the decision-
making process have a clear understanding of them and
their implications. Third, criteria need to be operational;
namely, the performance of the options against the criteria
should be measurable. Fourth, it is crucial that criteria are
non-redundant, i.e. there should be no overlap or double
counting between the different criteria, otherwise the eli-
cited criteria weights would not be accurate and, conse-
quently the overall results would be misleading. Finally,
criteria need to be concise, such that a small number that
can adequately capture the decision problem should be
used, striving for simplicity and parsimony, rather than
complexity.
Fig. 3 Value tree hierarchies and data sources using a multiple criteria decision analysis (MCDA) framework for value assessment
Table 1 Diffferent approaches for selecting objectives and criteria
Approach ‘Value-focused thinking’ [36] ‘Alternative-focused thinking’ [37] ‘Value alternative hybrid thinking’
Decription Objectives and criteria selected first prior
to the identification or assessment of the
alternative options
Options first compared so that
objectives and criteria emerge
based on their attributes
Generic set of objectives and criteria created




Top-down approach Bottom-up approach Top-down followed by bottom-up
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The aggregation stage is very important because it
produces the overall value scores of alternative treatments.
In order to enable the use of simple aggregation rules (e.g.
additive value models, where scores and weights of the
different individual criteria are multiplied and then added
altogether in a weighted average manner), preference
independence between the different criteria needs to be
upheld [26]. Preference independence is a key property; it
implies that the preference scores of one criterion for an
option can be assigned independently of the knowledge of
preference scores on the remaining criteria. It should be
noted that preference independence is not the same as
statistical independence; two different criteria attributes
could be statistically dependent but at the same time
preference independent and vice versa. If this requirement
is not observed, an additive aggregation function should
not be employed unless the criteria are restructured to
combine non-preference-independent criteria into com-
bined criteria.
If preference independence cannot be satisfied, then
more complex aggregation rules (e.g. multiplicative pref-
erence functions) would have to be applied to combine
scores with weights. Simpler aggregation rules are pre-
ferred over more complicated rules in most cases, mainly
because they are simple and easy for decision makers to
understand.
3.3 Key Attribute Properties
For selected attributes to be adequate or meaningful, suf-
ficient properties require them to be unambiguous (in that a
clear relationship should exist between the consequences of
an option and the levels of attribute used to describe these
consequences), comprehensive (the attribute levels should
cover the full range of consequences), direct (the attribute
levels should describe the consequences of alternative
options as directly as possible), operational (information
required for the attributes can be collected in practice and
value trade-offs—between the objectives or criteria—can
be made), and understandable (the consequences and value
trade-offs are readily understood and communicated across
the decision makers and other stakeholders by using the
attribute) [39]. For an additive value model to be used,
attributes should be preference independent.
A suggested systematic methodology to maximise the
probability of selecting the best possible attributes initially
involves an aim for a single natural attribute, namely one
that is in general use and has a common interpretation
measuring directly the degree to which an objective or a
criterion is met. If no such single attribute is appropriate
then a set (i.e. more than one) of natural attributes should
be considered that adequately describe objective/criteria
consequences. If this is not possible, exploration of
‘constructing’ attributes that directly measure conse-
quences should be attempted. Such attributes are explicitly
developed to measure directly the achievement of an
objective. A proxy attribute, i.e. a less informative attribute
that indirectly measures a criterion of concern, should be
selected only after careful consideration and following the
elimination of constructed attributes [39].
4 From Methodological Robustness to Practical
Relevance in the HTA Context
Very often, decision makers and even decision-analysis
researchers applying MCDA do not pay sufficient attention
to the theoretical foundations of MCDA and the different
set of properties that the MCDA models need to possess.
Recent evidence has shown that only one healthcare
MCDA study explained that criteria were defined to meet
MCDA requirements such as avoiding double counting
[40], with others acknowledging as a concern the fact that
MCDA responders might not understand some of the
attributes being used [41], possibly because of difficulties
in interpreting the meaning of the respective attribute
performance [42].
Taking into consideration that MCDA in itself posits a
departure from currently used HTA techniques, the appli-
cation of an MCDA approach and its principles in the
context of HTA requires careful reflection on a number of
fronts. First, it is important to clarify whose preferences to
consider. Assuming that an HTA agency acts as a proxy
decision maker, then it would be appropriate to adopt the
perspective of the respective HTA agency. For example, if
the decision context is England, France, or Sweden, it
would be reasonable to adopt the perspective of the
National Institute for Health and Care Excellence (NICE),
the Haute Autorite de Sante (HAS) and the Dental and
Pharmaceutical Benefits Board (TLV), respectively. Con-
sequently, any social judgements individual HTA agencies
adopt, including the participants and their preferences, will
need to reflect the particularities of each setting. As dif-
ferent countries or settings are likely to have different
priorities and objectives, the analysis should be tailormade
to their needs. Alternatively, if the adoption of such an
existing perspective is not possible, some formal stake-
holder analysis could be used to identify the key players
that should be involved [43].
A second but related issue is how to combine the pref-
erences of individual stakeholders. Ideally, a consensus
approach should be aimed for, through which a single
agreed value judgement (i.e. score, weight) would be
derived. Alternatively, if mathematical aggregation is used,
the median of responders’ preferences could be used,
especially in settings where motivational biases from some
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stakeholders exist (i.e. strongly against vs. strongly in
favour). In any case, the complete range of value judge-
ments should be recorded and used for sensitivity analysis,
where the impact of different scores and weights on the
options’ total value scores would be tested.
A third practical issue relates to the evidence require-
ments and their availability. While a criticism of MCDA
has been that it requires more evidence than standard HTA
approaches to populate the criteria, in practice, the same
evidence that is required for standard HTA approaches can
be used in the context of an MCDA model. Even if certain
items of information may not be available, they could be
readily collectable, or at least able to be proxied through
expert opinion.
The consistency of results would be a fourth important
issue subject to criticism. Would the results be consistent
within the same setting or could inconsistencies act as an
obstacle to homogeneous decisions? If the value analysis is
evidence based, the results are likely to be different if the
participants whose preferences are considered have dif-
ferent value judgements (i.e. different value functions and
weights). This highlights the importance of the context
wherein MCDA methods should be applied. Indeed, they
should act mainly as decision-aiding tools to support
healthcare resource priority setting conducted by the
decision maker.
5 ‘Incremental’ Versus ‘Clean Slate’ MCDA
Approaches and Link to Policy Making
The application of MCDA in current HTA practices has
been criticised partly because the criteria are mainly per-
ceived as attributes of benefit and the perception that cost
and uncertainty or relevance of the evidence cannot be
accounted for as criteria [44]. In turn, costs can be con-
sidered by incorporating the ‘impact on costs’ as a crite-
rion, other than the purchasing cost of the treatment itself,
which is essentially looking at savings or increased outlays.
Uncertainty of evidence could instead be considered
through the incorporation of penalty functions that may be
added when significant uncertainty exists, possibly due to
poor evidence quality, reducing the performance scores of
relevant options. For example, if the clinical data relating
to an OS gain are regarded as highly uncertain for any
reasons relating to the external and/or internal validity of
the clinical trial/data, then the performance score of the
observed OS gain for the particular treatment could be
reduced by a significant factor, e.g. 25–50 %, based on
expert opinion. As identified through a recent review, a
number of other formal approaches also exist to quantify
and incorporate uncertainty when conducting MCDA for
healthcare decisions, the most commonly used being fuzzy
set theory, probabilistic sensitivity analysis, deterministic
sensitivity analysis, Bayesian framework and grey theory
[45].
Another consideration relates to the appropriate process
of eliciting weights, and the argument that if they are to
emerge during the decision-making process it will prove
difficult to achieve predictability, consistency and
accountability, but also that scientific and social value
judgements might become mixed and prone to strategic
behaviour, with pre-specified weights being the way for-
ward [44]. Indeed, producing global weights that are
applicable across all decision contexts would seem a very
challenging task; however, weights elicited ex ante would
be hardly accurate in capturing the precise trade-offs under
consideration for the reasons discussed in Sect. 2.3. By
contrast, eliciting weights ex post would be more reflective
of decision-maker preferences and less susceptible to
strategic manipulation; however, their application would be
mostly restricted at a local decision context. A further
source of criticism stems from the question of what attri-
butes of benefit are lost due to additional cost and whether
these attributes of benefit foregone can be accounted for by
including the incremental cost-effectiveness ratios (ICERs)
as criteria [44]. Given that cost effectiveness and cost are
not attributes of benefit, one would need to know what
additional costs are required to improve the composite
measure of benefit and what attributes of benefit will be
given up as a consequence of costs.
Some of the above criticisms arise chiefly when MCDA
is applied as a ‘supplementary’ approach to CEA to adjust
the ICER by incorporating additional parameters of value.
Instead, some of the above criticisms may be overcome by
using a ‘pure’ MCDA approach to derive value without the
use of CEA (also described as ‘incremental’ and ‘clean
slate’ approaches, respectively [20]). In any case, further
research would be needed to fully address some of the
remaining practical limitations.
The aggregate metric of value emerging from the
MCDA process (the value index) is more encompassing in
nature, as multiple evaluation criteria are incorporated in
the analysis. By adopting this value index metric for each
option as the benefit component and incorporating the cost
of purchasing the different options, the cost per incremental
MCDA value unit gained, i.e. the incremental cost value
ratio(s) (ICVR), could act as the basis of allocating
resources in a way comparable to that of an ICER; for
instance, options with lower ICVRs would be interpreted as
more valuable and could be prioritised versus options with
higher ICVRs. Based on this approach, issues relating to
the definition of efficiency through the establishment of
thresholds that reflect opportunity costs would still need to
be addressed; however, they lie outside the scope of this
article.
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The resulting value index and its value scores would be
context specific, reflecting stakeholder preferences: the
value index incorporates value judgements and preferences
for a set of options based on a group of criteria, all of which
can be informed through stakeholder input. Unless identi-
cal value judgements and preferences are assumed for the
same group of criteria, a value score for an option in one
setting could be different from that in another setting. The
MCDA process, as proposed in this paper, respects stake-
holder preferences in individual settings, whilst reducing
decision heterogeneity by introducing clarity, objectivity
and greater transparency about the criteria based on which
decisions can be shaped.
6 Conclusion
We have proposed a methodological process outlining the
use of MCDA in the context of HTA based on MAVT
methods and the respective phases and stages of such a
process. Although a variety of MCDA techniques exist, it
is likely that the most important stages that act as the
foundations to the analysis are the establishment of
objectives and the definition of criteria and attributes. We
have focused on best practice requirements, as reflected
through the appropriate properties needed for criteria and
attribute selection, all of which feed into the model-
building phase.
Compared with economic evaluation techniques, such as
CEA, HTA through MCDA is found to have a number of
important advantages. These include the multiplicity of
criteria that can be used to assess value, the explicit
weights that are assigned to reflect differences in the rel-
ative importance of the criteria, the extensive stakeholder
engagement across all stages and the transparent nature of
the MCDA process, leading to a rounded, flexible,
encompassing and transparent approach to value assess-
ment and appraisal. Finally, because of the way MCDA is
structured, it does facilitate a decision-support system,
incorporating important trade-offs as part of the assessment
process, whereas in traditional CEA such trade-offs may be
considered on an ad hoc basis as part of the appraisal
process to inform decision making. Because of its char-
acteristics, HTA through MCDA could be a reasonable
resource-allocation tool that, among others, incorporates a
more holistic approach to value.
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